Navigation Links
Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development
Date:11/3/2008

SAN DIEGO, Nov. 3 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference -- AD/PD 2009 -- Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.


'/>"/>
SOURCE Avineuro Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. TCT update: press conference schedule announced for TCT
2. Balzan Foundation announced 2008 prize winners
3. 2008 Champions of Health Award Winners Announced
4. New Health Knowledge Base and Semantic Search Engine Announced
5. New HIV Infection Figures from CDC to be Announced on Aug. 3 Underscore Need for National AIDS Strategy for the U.S.
6. Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenues 2008 KEY TO THE CURE Campaign
7. Medpedia Announced, Worlds Largest Collaborative Online Encyclopedia of Medicine and Health
8. Texas Detailed Products Today Announced the Second Generation Detail Bag: Skinceuticals Chooses the Detail Bag II Sample Case for all its Pharmaceutical Representatives
9. Cosmetic Innovators of The Year Announced
10. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
11. £20M health research collaboration announced for the southwest England
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... According to an ... one in four girls are sexually abused before the age of 18. Of those ... to tell her story and others. , In her new book, Lyah! Lyah! ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... urgent care facilities designed to automate and improve the rapid diagnosis, triage and ... is demonstrating their platform, application, and mobile experience for the first time at ...
(Date:5/2/2016)... ... ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where ... 5 US Cities with the Highest Plastic Rates .” The other cities that made ... calculated using a survey by RealSelf and combining that data with the number ...
(Date:5/2/2016)... ... ... For many artists, the act of blending paint is based on intuition ... , Using the new, highly precise METTLER TOLEDO ML204T balance to weigh and ... to his works. What’s more, it has allowed him to recreate these shades and ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept secrets for ... & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive options for ... and go home or back to work without having to wear recovery garments or ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
Breaking Medicine Technology: